Équipe de Direction
Équipe de Direction
Amine Selmani, PhD - Founder, Executive Chairman
Dr. Selmani is a founder of Oligo Medic, his third orthopedic venture. He holds multiple patents on chitosan and derivatives thereof, for orthopedic applications. Dr. Selmani studied in Bordeaux University and has PhD in Material Sciences (1985) from the University of Montreal. He is a former Professor at the engineering school, École Polytechnique de Montréal. Dr. Selmani’s research in biomaterials and biotechnologies led him to incorporate BioSyntech in 1995 and be part of its executive team as CEO and Chairman of the Board for almost 10 years. During his tenure, Dr. Selmani took this biotechnology company public on both Nasdaq and TSX.
Also, Dr. Selmani founded in 1992 POLNOR (Polytechnique-Noranda), a large group of engineers and professionals, with the mandate to provide higher value to the Noranda amorphous selenium and other byproducts. Big budgets coming from Noranda, Natural Sciences and Engineering Research Council of Canada, 3M and The Ecole Polytechnique de Montreal allowed the development of a high-resolution selenium-based direct X-ray detectors, specifically designed for full-field digital mammography used in most radiology centers in the world and commercialized by the well-known company in the field, Analogic.
Jerett Creed - Chief Executive Officer
Mr. Creed has more than 20 years of MedTech experience with leadership roles in international commercialization, capital markets and business development. He has participated in M&A transactions exceeding $650M including two IPOs. Mr. Creed was founder and CEO of Cardigant Medical, a former public company, focused on the development and commercialization of novel peptide mimetics for treating vascular disease.
Mr. Creed began his career with Johnson & Johnson and spent more than a decade with the Company. Prior to assuming the role of CEO for Oligo Medic, Mr. Creed was in charge of launching JointRep throughout Latin America. Mr. Creed holds a MS in Accounting and a BSc in Engineering, both from the University of Miami.
Monique Jarry - VP Finance & HR
Ms Jarry holds a BA and MA (1991) from University of Montreal. She implemented many accounting systems in public companies listed in Nasdaq BB and on TSX. Ms. Jarry supervised all the financial aspects of a private investment company from 1992 until 2010, when she joined Oligomedic as a VP Finances.
Donald Olds, MSc, MBA
Mr. Olds is the former President and CEO of the NEOMED Institute, an R&D organization dedicated to advancing Canadian research discoveries to commercial success. Prior to NEOMED, he was the COO of Telesta Therapeutics Inc., a TSX-listed biotechnology company, where he was responsible for finance and investor relations, manufacturing operations, business development, human resources and strategy. In 2016, he led the successful sale of Telesta to a larger public biotechnology company. Prior to Telesta, he was President and CEO of Presagia Corp., and CFO and COO of Aegera Therapeutics, where he was responsible for clinical operations, business development, finance, and mergers and acquisitions. At both Telesta and Aegera, Mr. Olds was responsible for raising more than $100 million in equity financing and leading regional and global licensing transactions with life sciences companies. Mr. Olds is currently Director of Goodfood Market Corp, Chairman of Oxfam Quebec and Director of Presagia Corp. He has extensive past corporate governance experience serving on the boards of private and public for-profit and not-for-profit organizations. He holds an MBA (Finance & Strategy) and M.Sc. from McGill University.
Howard Levy, M.B.B.Ch, PhD, M.M.M.
Dr. Levy has over 25 years of experience in the pharmaceutical industry and has an established track record of building effective clinical and medical organizations and in directing successful drug development. Dr. Levy is currently the Chief Medical Officer for Catalyst Biosciences.
Dr. Levy practiced as an intensivist with specialty board certification in Internal Medicine, Pulmonary and Intensive Care. Since 2010 he has advised public and private biotechnology and medical device companies on clinical and drug development strategy and execution. He has served on many clinical trial committees including Data Safety Monitoring Boards, Health Economic assessment and Clinical Evaluation Committees. Dr. Levy has more than 100 peer-reviewed publications and chapters in books.